Neonatal antiphospholipid syndrome
diseaseOn this page
Also known as neonatal antiphospholipid antibody syndromeneonatal Hughes syndrome
Summary
Neonatal antiphospholipid syndrome (MONDO:0018357) is a disease. A subtype of secondary neonatal autoimmune disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: <1 / 1 000 000 (Worldwide) [Orphanet-validated]
Clinical features
Epidemiology
Prevalence records
2 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Cases/families | 34 | Worldwide | Validated | |
| Point prevalence | <1 / 1 000 000 | Worldwide | Validated |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | neonatal antiphospholipid syndrome |
| Mondo ID | MONDO:0018357 |
| Orphanet | 398097 |
| UMLS | C4751518 |
| MedGen | 1664921 |
| GARD | 0021644 |
| Is cancer (heuristic) | no |
Also known as: neonatal antiphospholipid antibody syndrome · neonatal Hughes syndrome
Disease family
Classification path: disease › human disease › disease by body system or component › immune system disorder › autoimmune disease › secondary neonatal autoimmune disease › neonatal antiphospholipid syndrome
Related subtypes (5): transient neonatal myasthenia gravis, neonatal autoimmune hemolytic anemia, neonatal dermatomyositis, neonatal lupus erythematosus, neonatal scleroderma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.